Charles River Laboratories
416 hedge funds and large institutions have $5.91B invested in Charles River Laboratories in 2020 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 166 increasing their positions, 129 reducing their positions, and 56 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 4 → 12 (+8)
164% more call options, than puts
Call options by funds: $29.6M | Put options by funds: $11.2M
29% more repeat investments, than reductions
Existing positions increased: 166 | Existing positions reduced: 129
11% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 56
1% more funds holding
Funds holding: 413 → 416 (+3)
2.11% less ownership
Funds ownership: 96.87% → 94.76% (-2.1%)
18% less capital invested
Capital invested by funds: $7.23B → $5.91B (-$1.32B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$61.4M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$52.9M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$39.9M |
| 4 |
SCM
Sandler Capital Management
New York
|
+$27.2M |
| 5 |
CIM
Confluence Investment Management
St. Louis,
Missouri
|
+$25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$84.8M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$60.6M |
| 3 |
Millennium Management
New York
|
-$49.6M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$47.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.7M |
CRL Hedge Fund Activity: Q1 2020 in Review
416 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q1 2020, worth a combined $5.91B — down 18% from $7.23B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new CRL positions and 56 closed out — a net gain of 6 holders — while 166 added to existing stakes and 129 trimmed.
The largest buyer was HealthCor Management, adding an estimated $61.4M. The largest seller was Kayne Anderson Rudnick Investment Management, cutting an estimated $84.8M.
- 416 institutional investors held Charles River Laboratories (CRL) as of Q1 2020, up from 413 in Q4 2019.
- Funds reported $5.91B of Charles River Laboratories stock for Q1 2020, down 18% quarter-over-quarter.
- 62 funds opened new Charles River Laboratories positions in Q1 2020 and 56 closed out, a net change of +6 holders.
- The largest Charles River Laboratories buyer in Q1 2020 was HealthCor Management, an estimated $61.4M added.
- The largest Charles River Laboratories seller in Q1 2020 was Kayne Anderson Rudnick Investment Management, an estimated $84.8M sold.
Based on aggregated 13F filings for Q1 2020.